Phase 1 Clinical Trial Results of a Gene Therapy for Spinal Muscular Atrophy

Phase 1 Clinical Trial Results of a Gene Therapy for Spinal Muscular Atrophy

Health In Focus
RSS Email Print This Page Comment bookmark
Font : A-A+

Highlights:

  • AVXS-101, a gene therapy for spinal muscular atrophy type 1 (SMA1) shows promising results in its phase 1 clinical trial.
  •   A one-time high dose intravenous infusion was shown to extend the survival of patients with SMA1.
  • Motor skills like head holding, rolling over, sitting and even walking were observed in patients who received the therapy.
A recent study published in the New England Journal of Medicine reports that a one-time high dose of AVXS-101, a gene therapy for spinal muscular atrophy type 1 (SMA1) extends survival and helps improve motor function in patients. SMA is a neuromuscular disease caused by a single mutation in the SMN gene which results in muscle wasting and lack of motor skills and control. SMA type 1 (SMA1) is the most severe form and is apparent at birth. Children with SMA1 have a life span of 2 years and there is no treatment presently for the devastating disease.

SMA1

SMA1 is a progressive, childhood, neuromuscular disease that results in muscle weakness and wastage. It is caused due to inadequate production of a protein called survival motor neuron (SMN) encoded by the SMN gene. The protein is essential for motor neuron functions. As a result, children with SMA1 fail to meet motor milestones and usually die by the age of 2 or require permanent mechanical ventilation in order to survive a litter longer.

Phase 1 clinical trial

The study was conducted by research teams at the Nationwide Children's Hospital and the Ohio State University College of Medicine in collaboration with AveXis, Inc. AveXis, Inc is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases.
Phase 1 Clinical Trial Results of a Gene Therapy for Spinal Muscular Atrophy

The study was based on administering a one-time intravenous injection of the SMN gene (AVXS-101) using a modified adeno-associated virus serotype 9 (AAV9) for delivery. It was tested on 15 patients.

12 of these patients received a high dose and 3 received a low dose of AVXS-101. The results suggested that patients who received a high dose showed improved motor function and required lesser supportive care.

The following were observed in the 12 patients who received the high dose of AVXS-101.
  • 92 percent of patients achieved head control
  • 75 percent of patients could roll over
  • 92 percent of patients could sit with assistance
  • 75 percent of patients are now sitting for 30 seconds or longer
  • 2 patients could crawl, pull to stand and stand and walk independently
As a natural course of disease progression, spinal muscular atrophy patients require nutritional and respiratory support by the age of 12 months. They are also incapable of swallowing or speaking effectively and are almost never able to sit.

Of the patients who received the high dose of AVXS-101,
  • 11 patients are able to speak
  • 11 patients are fed orally
  • 7 do not require bi-level positive airway pressure
as of data assessed until August 7, 2017.

Development of the gene therapy

The current gene therapy is the result of almost three decades of foundational research by teams at Nationwide Children's and Ohio State's Wexner Medical Center. The SMA mouse model was a major achievement created by Arthur Burghes, PhD, of Ohio State. This is the standard model where all therapies including AVXS-101 are initially tested. Brian Kaspar, PhD, from Nationwide Children's discovered that AAV9 vector was capable of delivering the SMN gene to the motor neurons in the brain by crossing the blood brain barrier when injected into the vascular system. This is the basis of the drug delivery in the current gene therapy AVXS-101. The phase 1 clinical trials in humans were possible only after proving that this gene therapy could reverse the SMN protein deficiency and improve and stabilize SMA in a large animal model.

This is what Dr. Kaspar, now serving as Chief Scientific Officer at AveXis had to say about AVXS-101: "At AveXis, we are enormously pleased to see that all children who received AVXS-101 are alive and free of permanent ventilatory support at 20 months of age and older - an age where, sadly, only eight percent of untreated children with SMA Type 1 are expected to survive without permanent breathing support."

References:

  1. Jerry R. Mendell et l. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med 2017; 377:1713-1722 November 2, 2017 DOI: 10.1056/NEJMoa1706198
  2. Spinal Muscular Atrophy (SMA) - (https:my.clevelandclinic.org/health/articles/spinal-muscular-atrophy-sma)

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

DNA Finger Printing Clinical Trials Clinical Trials - The Past and The Future Clinical Trials - Different Phases of the trial Reiki and Pranic Healing Genetic Testing of Diseases Pancreas Amyotrophic Lateral Sclerosis (ALS) Placebo Effects: Rare Insights Weaver Syndrome 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...